You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEpinastine
Accession NumberDB00751  (APRD00043)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionEpinastine is used for the prevention of itching associated with allergic conjunctivitis. It has a multi-action effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding to both the H1- and H2-receptors to stop itching and provide lasting protection, and 3. prevents the release of proinflammatory chemical mediators from the blood vessel to halt progression of the allergic response.
Structure
Thumb
Synonyms
(+-)-Epinastine
3-amino-9,13b-dihydro-1H-Dibenz(c,F)imidazo(1,5-a)azepine
Epinastin
Epinastina
Epinastine
Epinastinum
External Identifiers
  • WAL 801 Cl
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Elestatsolution/ drops.5 mg/mLophthalmicAllergan, Inc.2004-01-19Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Epinastine Hydrochloridesolution/ drops.5 mg/mLophthalmicPerrigo Company2011-11-01Not applicableUs
Epinastine Hydrochloridesolution/ drops.5 mg/mLophthalmicBreckenridge Pharmaceutical, Inc.2013-11-05Not applicableUs
Epinastine Hydrochloridesolution.5 mg/mLophthalmicApotex Corp.2011-10-31Not applicableUs
Epinastine Hydrochloridesolution.5 mg/mLophthalmicSun Pharmaceutical Industries Limited2011-11-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlegainKyorin Rimedio
AlenapionChoseido Pharmaceutical
AlesionBoehringer Ingelheim
AlesiotecNihon Yakuhin Kogyo
AlketPoen
AllernothinMorishita Jintan
AllerstinDong Koo
AlpeedDaito
AplatinTaiyo Pharmaceutical
ArestenIl Sung
AsmotTatsumi Kagaku
AtergitRoemmers
AzusaleonShiono Kemikaru
ElpinanTowa Yakuhin
EpinastineKotobuki Seiyaku
EpinazionMedisa Shinyaku
EpioftalFarmindustria
FlurinolBoehringer Ingelheim
HelvottzYoshindo
Kai lai ZhiCarelife Pharmaceutical Co Ltd
PinasionTaisho Yakuhin
PurivistAllergan
RelenastineLansier
RelestatAllergan
TalercAché
TimkentNisshin Seiyaku
YupitelIwaki Seiyaku
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Epinastine Hydrochloride
ThumbNot applicableDBSALT000961
Categories
UNIIQ13WX941EF
CAS number80012-43-7
WeightAverage: 249.3104
Monoisotopic: 249.126597495
Chemical FormulaC16H15N3
InChI KeyInChIKey=WHWZLSFABNNENI-UHFFFAOYSA-N
InChI
InChI=1S/C16H15N3/c17-16-18-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)19(15)16/h1-8,15H,9-10H2,(H2,17,18)
IUPAC Name
2,4-diazatetracyclo[12.4.0.0²,⁶.0⁷,¹²]octadeca-1(18),3,7,9,11,14,16-heptaen-3-amine
SMILES
NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassDibenzazepines
Direct ParentDibenzazepines
Alternative Parents
Substituents
  • Dibenzazepine
  • Azepine
  • Benzenoid
  • 2-imidazoline
  • Tertiary amine
  • Guanidine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the prevention of itching associated with allergic conjunctivitis.
PharmacodynamicsEpinastine is an antihistamine and an inhibitor of histamine release from the mast cell for topical administration to the eyes. Epinastine is indicated for the prevention of itching associated with allergic conjunctivitis. Epinastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from the mast cell. Epinastine is selective for the histamine H1-receptor and has affinity for the histamine H2 receptor. Epinastine also possesses affinity for the a1-, a2-, and 5-HT2 -receptors. Epinastine does not penetrate the blood/brain barrier and, therefore, is not expected to induce side effects of the central nervous system.
Mechanism of actionEpinastine has a multiaction effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding to both the H1- and H2-receptors to stop itching and provide lasting protection, and 3. prevents the release of proinflammatory chemical mediators from the blood vessel to halt progression of the allergic response.
Related Articles
AbsorptionThe absolute bioavailability of epinastine is about 40%.
Volume of distributionNot Available
Protein binding64%
Metabolism

Mainly excreted unchanged, less than 10% metabolized.

Route of eliminationEpinastine is mainly excreted unchanged. The renal elimination is mainly via active tubular secretion.
Half life12 hours
Clearance
  • 56 L/hr [patients with allergic conjunctivitis receiving one drop of ELESTAT® ophthalmic solution in each eye twice daily for seven days]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9923
Blood Brain Barrier+0.9787
Caco-2 permeable+0.5766
P-glycoprotein substrateSubstrate0.5665
P-glycoprotein inhibitor INon-inhibitor0.8193
P-glycoprotein inhibitor IINon-inhibitor0.5736
Renal organic cation transporterInhibitor0.7994
CYP450 2C9 substrateNon-substrate0.8676
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.5422
CYP450 1A2 substrateNon-inhibitor0.5686
CYP450 2C9 inhibitorNon-inhibitor0.9243
CYP450 2D6 inhibitorNon-inhibitor0.5228
CYP450 2C19 inhibitorNon-inhibitor0.8702
CYP450 3A4 inhibitorNon-inhibitor0.6566
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.726
Ames testAMES toxic0.5689
CarcinogenicityNon-carcinogens0.9144
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7509 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9353
hERG inhibition (predictor II)Non-inhibitor0.8419
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Allergan inc
Packagers
Dosage forms
FormRouteStrength
Solution/ dropsophthalmic.5 mg/mL
Solutionophthalmic.5 mg/mL
Prices
Unit descriptionCostUnit
Elestat 0.05% Solution 5ml Bottle116.58USD bottle
Elestat 0.05% eye drops22.94USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7429602 No2000-11-292020-11-29Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point205-208 °CNot Available
logP3.51BIOBYTE (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.163 mg/mLALOGPS
logP2.53ALOGPS
logP3.07ChemAxon
logS-3.2ALOGPS
pKa (Strongest Basic)8.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.62 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity76.9 m3·mol-1ChemAxon
Polarizability27.33 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Akiharu Isowaki, Tomoko Nakajima, Akira Ohtori, “Percutaneously Absorptive Ophthalmic Preparation Comprising Epinastine.” U.S. Patent US20090143359, issued June 04, 2009.

US20090143359
General References
  1. Walther G, Daniel H, Bechtel WD, Brandt K: New tetracyclic guanidine derivatives with H1-antihistaminic properties. Chemistry of epinastine. Arzneimittelforschung. 1990 Apr;40(4):440-6. [PubMed:1972625 ]
  2. Schilling JC, Adamus WS, Kuthan H: Antihistaminic activity and side effect profile of epinastine and terfenadine in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1990 Dec;28(12):493-7. [PubMed:1982280 ]
External Links
ATC CodesR06AX24S01GX10
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (113 KB)
MSDSDownload (57 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Epinastine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Epinastine.
AbciximabEpinastine may increase the anticoagulant activities of Abciximab.
AbciximabAbciximab may increase the antiplatelet activities of Epinastine.
AbirateroneThe metabolism of Epinastine can be decreased when combined with Abiraterone.
AcenocoumarolEpinastine may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe serum concentration of Epinastine can be increased when it is combined with Acetaminophen.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Epinastine is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may increase the antiplatelet activities of Epinastine.
AfatinibThe serum concentration of Epinastine can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Epinastine can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Epinastine can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Epinastine can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Epinastine can be increased when it is combined with Alfentanil.
AlprostadilEpinastine may increase the antiplatelet activities of Alprostadil.
AlteplaseEpinastine may increase the anticoagulant activities of Alteplase.
ALX-0081Epinastine may increase the anticoagulant activities of ALX-0081.
AmantadineThe serum concentration of Epinastine can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Epinastine can be increased when it is combined with Aminohippuric acid.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Epinastine is combined with Aminosalicylic Acid.
AmiodaroneThe serum concentration of Epinastine can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Epinastine can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Epinastine can be increased when it is combined with Amlodipine.
AmphetamineAmphetamine may decrease the sedative activities of Epinastine.
AmprenavirThe serum concentration of Epinastine can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Epinastine can be increased when it is combined with Amsacrine.
AnagrelideEpinastine may increase the anticoagulant activities of Anagrelide.
AnagrelideAnagrelide may increase the antiplatelet activities of Epinastine.
AncrodEpinastine may increase the anticoagulant activities of Ancrod.
AnistreplaseEpinastine may increase the anticoagulant activities of Anistreplase.
Antithrombin III humanEpinastine may increase the anticoagulant activities of Antithrombin III human.
ApixabanEpinastine may increase the anticoagulant activities of Apixaban.
AprepitantThe serum concentration of Epinastine can be increased when it is combined with Aprepitant.
ArdeparinEpinastine may increase the anticoagulant activities of Ardeparin.
ArgatrobanEpinastine may increase the anticoagulant activities of Argatroban.
ArgatrobanArgatroban may increase the antiplatelet activities of Epinastine.
ArtemetherThe metabolism of Epinastine can be decreased when combined with Artemether.
AstaxanthinEpinastine may increase the anticoagulant activities of Astaxanthin.
AstemizoleThe serum concentration of Epinastine can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Epinastine.
AtazanavirThe serum concentration of Epinastine can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Epinastine can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Epinastine can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Epinastine can be increased when it is combined with Atorvastatin.
AzelastineThe serum concentration of Epinastine can be increased when it is combined with Azelastine.
AzelastineEpinastine may increase the antiplatelet activities of Azelastine.
AzithromycinThe serum concentration of Epinastine can be increased when it is combined with Azithromycin.
BatroxobinEpinastine may increase the anticoagulant activities of Batroxobin.
BecaplerminEpinastine may increase the anticoagulant activities of Becaplermin.
BemiparinEpinastine may increase the anticoagulant activities of Bemiparin.
BenzocaineThe serum concentration of Epinastine can be increased when it is combined with Benzocaine.
BenzphetamineBenzphetamine may decrease the sedative activities of Epinastine.
Benzylpenicilloyl PolylysineEpinastine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BepridilThe serum concentration of Epinastine can be increased when it is combined with Bepridil.
BeraprostEpinastine may increase the anticoagulant activities of Beraprost.
BeraprostBeraprost may increase the antiplatelet activities of Epinastine.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Epinastine.
BetaxololThe metabolism of Epinastine can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Epinastine can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Epinastine can be increased when it is combined with Biperiden.
BivalirudinEpinastine may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe metabolism of Epinastine can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Epinastine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Epinastine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Epinastine.
BosutinibThe serum concentration of Epinastine can be increased when it is combined with Bosutinib.
BromocriptineThe serum concentration of Epinastine can be increased when it is combined with Bromocriptine.
BuprenorphineThe serum concentration of Epinastine can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Epinastine can be decreased when combined with Bupropion.
BuspironeThe serum concentration of Epinastine can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Epinastine can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Epinastine can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Epinastine can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Epinastine can be increased when it is combined with Candesartan.
CangrelorEpinastine may increase the anticoagulant activities of Cangrelor.
CangrelorCangrelor may increase the antiplatelet activities of Epinastine.
CaptoprilThe serum concentration of Epinastine can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Epinastine can be decreased when it is combined with Carbamazepine.
CarvedilolThe serum concentration of Epinastine can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Epinastine can be increased when it is combined with Caspofungin.
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Epinastine.
CefpodoximeEpinastine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
CefuroximeEpinastine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
CelecoxibThe metabolism of Epinastine can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Epinastine can be increased when it is combined with Ceritinib.
CertoparinEpinastine may increase the anticoagulant activities of Certoparin.
ChloroquineThe serum concentration of Epinastine can be increased when it is combined with Chloroquine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Epinastine.
ChlorpromazineThe serum concentration of Epinastine can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Epinastine can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Epinastine can be increased when it is combined with Chlorprothixene.
CholecalciferolThe metabolism of Epinastine can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Epinastine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Epinastine can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Epinastine can be increased when it is combined with Cilazapril.
CilostazolEpinastine may increase the anticoagulant activities of Cilostazol.
CilostazolCilostazol may increase the antiplatelet activities of Epinastine.
CimetidineThe serum concentration of Epinastine can be decreased when it is combined with Cimetidine.
CinacalcetThe metabolism of Epinastine can be decreased when combined with Cinacalcet.
CiprofloxacinThe serum concentration of Epinastine can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Epinastine can be increased when it is combined with Citalopram.
Citric AcidEpinastine may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe serum concentration of Epinastine can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Epinastine can be decreased when combined with Clemastine.
ClobazamThe metabolism of Epinastine can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Epinastine can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Epinastine can be increased when it is combined with Clomipramine.
ClopidogrelEpinastine may increase the anticoagulant activities of Clopidogrel.
ClopidogrelThe metabolism of Epinastine can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Epinastine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Epinastine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Epinastine can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Epinastine can be decreased when combined with Cocaine.
ColchicineThe serum concentration of Epinastine can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Epinastine can be increased when it is combined with Colforsin.
CollagenaseThe risk or severity of adverse effects can be increased when Epinastine is combined with Collagenase.
ConivaptanThe serum concentration of Epinastine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Epinastine can be decreased when combined with Crizotinib.
CyclophosphamideThe serum concentration of Epinastine can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Epinastine can be decreased when combined with Cyclosporine.
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Epinastine.
Dabigatran etexilateEpinastine may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Epinastine.
DaclatasvirThe serum concentration of Epinastine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Epinastine can be increased when it is combined with Dactinomycin.
DalteparinEpinastine may increase the anticoagulant activities of Dalteparin.
DanaparoidEpinastine may increase the anticoagulant activities of Danaparoid.
DarifenacinThe metabolism of Epinastine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Epinastine can be increased when it is combined with Darunavir.
DasatinibDasatinib may increase the anticoagulant activities of Epinastine.
DasatinibEpinastine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
DaunorubicinThe serum concentration of Epinastine can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Epinastine can be decreased when it is combined with Deferasirox.
DefibrotideEpinastine may increase the anticoagulant activities of Defibrotide.
DefibrotideDefibrotide may increase the antiplatelet activities of Epinastine.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Epinastine.
DelavirdineThe metabolism of Epinastine can be decreased when combined with Delavirdine.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Epinastine is combined with Deoxycholic Acid.
DesipramineThe serum concentration of Epinastine can be increased when it is combined with Desipramine.
DesirudinEpinastine may increase the anticoagulant activities of Desirudin.
DesloratadineThe serum concentration of Epinastine can be increased when it is combined with Desloratadine.
DesmoteplaseEpinastine may increase the anticoagulant activities of Desmoteplase.
DexamethasoneThe serum concentration of Epinastine can be decreased when it is combined with Dexamethasone.
DexmethylphenidateEpinastine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
DextranEpinastine may increase the anticoagulant activities of Dextran.
Dextran 40Epinastine may increase the anticoagulant activities of Dextran 40.
Dextran 70Epinastine may increase the anticoagulant activities of Dextran 70.
Dextran 75Epinastine may increase the anticoagulant activities of Dextran 75.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Epinastine.
DextromethorphanThe serum concentration of Epinastine can be increased when it is combined with Dextromethorphan.
DiclofenacThe serum concentration of Epinastine can be increased when it is combined with Diclofenac.
DicoumarolEpinastine may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Epinastine is combined with Diflunisal.
DigoxinThe serum concentration of Epinastine can be decreased when it is combined with Digoxin.
DihydroergotamineThe metabolism of Epinastine can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Epinastine can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Epinastine can be decreased when combined with Diphenhydramine.
DipyridamoleEpinastine may increase the anticoagulant activities of Dipyridamole.
DipyridamoleThe serum concentration of Epinastine can be increased when it is combined with Dipyridamole.
DitazoleEpinastine may increase the anticoagulant activities of Ditazole.
DoxazosinThe serum concentration of Epinastine can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Epinastine can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Epinastine can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Epinastine can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Epinastine can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Epinastine can be decreased when combined with Dronedarone.
Drotrecogin alfaEpinastine may increase the anticoagulant activities of Drotrecogin alfa.
DuloxetineThe metabolism of Epinastine can be decreased when combined with Duloxetine.
Edetic AcidEpinastine may increase the anticoagulant activities of Edetic Acid.
EdoxabanEpinastine may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Epinastine can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Epinastine can be increased when it is combined with Elbasvir.
EliglustatThe metabolism of Epinastine can be decreased when combined with Eliglustat.
EnalaprilThe serum concentration of Epinastine can be increased when it is combined with Enalapril.
EnoxaparinEpinastine may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Epinastine can be increased when it is combined with Enzalutamide.
EpoprostenolEpinastine may increase the anticoagulant activities of Epoprostenol.
EpoprostenolEpoprostenol may increase the antiplatelet activities of Epinastine.
EptifibatideEpinastine may increase the anticoagulant activities of Eptifibatide.
EptifibatideEptifibatide may increase the antiplatelet activities of Epinastine.
ErgonovineThe serum concentration of Epinastine can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Epinastine can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Epinastine.
ErythromycinThe metabolism of Epinastine can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Epinastine can be decreased when it is combined with Eslicarbazepine acetate.
EstramustineThe serum concentration of Epinastine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Epinastine can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Epinastine can be decreased when it is combined with Estrone.
Ethyl biscoumacetateEpinastine may increase the anticoagulant activities of Ethyl biscoumacetate.
EtoposideThe serum concentration of Epinastine can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Epinastine can be decreased when it is combined with Etravirine.
FelodipineThe serum concentration of Epinastine can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Epinastine can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Epinastine.
FexofenadineThe serum concentration of Epinastine can be increased when it is combined with Fexofenadine.
FibrinolysinEpinastine may increase the anticoagulant activities of Fibrinolysin.
FidaxomicinThe serum concentration of Epinastine can be increased when it is combined with Fidaxomicin.
FluconazoleThe metabolism of Epinastine can be decreased when combined with Fluconazole.
FluoxetineThe serum concentration of Epinastine can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Epinastine can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Epinastine can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Epinastine can be increased when it is combined with Flurazepam.
FluvoxamineThe metabolism of Epinastine can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumEpinastine may increase the anticoagulant activities of Fondaparinux sodium.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Epinastine.
FosamprenavirThe metabolism of Epinastine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Epinastine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Epinastine can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Epinastine can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Epinastine.
GefitinibThe serum concentration of Epinastine can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Epinastine can be increased when it is combined with Genistein.
GlucosamineGlucosamine may increase the antiplatelet activities of Epinastine.
GlyburideThe serum concentration of Epinastine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Epinastine can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Epinastine can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Epinastine can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Epinastine can be increased when it is combined with Haloperidol.
HeparinEpinastine may increase the anticoagulant activities of Heparin.
HirulogEpinastine may increase the anticoagulant activities of Hirulog.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Epinastine.
HydrocortisoneThe serum concentration of Epinastine can be increased when it is combined with Hydrocortisone.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Epinastine.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Epinastine is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Epinastine.
IbudilastEpinastine may increase the antiplatelet activities of Ibudilast.
Icosapent ethylEpinastine may increase the antiplatelet activities of Icosapent ethyl.
IdelalisibThe serum concentration of Epinastine can be increased when it is combined with Idelalisib.
IfenprodilEpinastine may increase the antiplatelet activities of Ifenprodil.
IloprostEpinastine may increase the anticoagulant activities of Iloprost.
IloprostIloprost may increase the antiplatelet activities of Epinastine.
ImatinibThe metabolism of Epinastine can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Epinastine can be increased when it is combined with Imipramine.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Epinastine.
IndomethacinThe serum concentration of Epinastine can be increased when it is combined with Indomethacin.
IsavuconazoniumThe metabolism of Epinastine can be decreased when combined with Isavuconazonium.
IsoniazidThe metabolism of Epinastine can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Epinastine can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Epinastine.
ItraconazoleThe serum concentration of Epinastine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Epinastine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Epinastine can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Epinastine can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Epinastine.
KetoconazoleThe serum concentration of Epinastine can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Epinastine can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Epinastine can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Epinastine.
LepirudinEpinastine may increase the anticoagulant activities of Lepirudin.
LevofloxacinThe serum concentration of Epinastine can be increased when it is combined with Levofloxacin.
LevothyroxineThe serum concentration of Epinastine can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Epinastine can be increased when it is combined with Lidocaine.
LimaprostLimaprost may increase the antiplatelet activities of Epinastine.
LiothyronineThe serum concentration of Epinastine can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Epinastine can be decreased when it is combined with Liotrix.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Epinastine.
LisinoprilThe serum concentration of Epinastine can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Epinastine can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Epinastine can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Epinastine can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Epinastine can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Epinastine can be decreased when combined with Lorcaserin.
LosartanThe serum concentration of Epinastine can be increased when it is combined with Losartan.
LovastatinThe metabolism of Epinastine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Epinastine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Epinastine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Epinastine can be decreased when combined with Lumefantrine.
MaprotilineThe serum concentration of Epinastine can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Epinastine can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Epinastine can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Epinastine can be increased when it is combined with Megestrol acetate.
MephentermineMephentermine may decrease the sedative activities of Epinastine.
MeprobamateThe serum concentration of Epinastine can be increased when it is combined with Meprobamate.
MesalazineThe risk or severity of adverse effects can be increased when Epinastine is combined with Mesalazine.
MethadoneThe serum concentration of Epinastine can be increased when it is combined with Methadone.
MethamphetamineMethamphetamine may decrease the sedative activities of Epinastine.
MethotrimeprazineThe metabolism of Epinastine can be decreased when combined with Methotrimeprazine.
MethylphenidateEpinastine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Epinastine.
MibefradilThe serum concentration of Epinastine can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Epinastine can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Epinastine can be decreased when it is combined with Midazolam.
MifepristoneThe metabolism of Epinastine can be decreased when combined with Mifepristone.
MilrinoneMilrinone may increase the antiplatelet activities of Epinastine.
MirabegronThe metabolism of Epinastine can be decreased when combined with Mirabegron.
MitomycinThe serum concentration of Epinastine can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Epinastine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Epinastine can be decreased when it is combined with Mitoxantrone.
ModafinilThe serum concentration of Epinastine can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Epinastine can be increased when it is combined with Morphine.
NadroparinEpinastine may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Epinastine can be decreased when it is combined with Nafcillin.
NaltrexoneThe serum concentration of Epinastine can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Epinastine can be increased when it is combined with Naringenin.
NCX 4016Epinastine may increase the anticoagulant activities of NCX 4016.
NCX 4016NCX 4016 may increase the antiplatelet activities of Epinastine.
NefazodoneThe serum concentration of Epinastine can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Epinastine.
NeostigmineThe serum concentration of Epinastine can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Epinastine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Epinastine can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Epinastine can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Epinastine can be decreased when it is combined with Nifedipine.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Epinastine.
NilotinibThe metabolism of Epinastine can be decreased when combined with Nilotinib.
NimesulideEpinastine may increase the antiplatelet activities of Nimesulide.
NisoldipineThe serum concentration of Epinastine can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Epinastine can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Epinastine can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Epinastine can be decreased when it is combined with Norethisterone.
ObinutuzumabThe risk or severity of adverse effects can be increased when Epinastine is combined with Obinutuzumab.
OlaparibThe metabolism of Epinastine can be decreased when combined with Olaparib.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Epinastine.
OmeprazoleThe serum concentration of Epinastine can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Epinastine can be increased when it is combined with Osimertinib.
OtamixabanEpinastine may increase the anticoagulant activities of Otamixaban.
P-NitrophenolThe serum concentration of Epinastine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Epinastine can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Epinastine can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Epinastine can be increased when it is combined with Palmitic Acid.
PanobinostatThe metabolism of Epinastine can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Epinastine can be increased when it is combined with Pantoprazole.
ParnaparinEpinastine may increase the anticoagulant activities of Parnaparin.
ParoxetineThe serum concentration of Epinastine can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Epinastine.
Peginterferon alfa-2bThe serum concentration of Epinastine can be decreased when it is combined with Peginterferon alfa-2b.
PentobarbitalThe metabolism of Epinastine can be increased when combined with Pentobarbital.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Epinastine.
Pentosan PolysulfateEpinastine may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Epinastine.
PerindoprilThe serum concentration of Epinastine can be increased when it is combined with Perindopril.
PhenindioneEpinastine may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of Epinastine can be decreased when it is combined with Phenobarbital.
PhenprocoumonEpinastine may increase the anticoagulant activities of Phenprocoumon.
PhenterminePhentermine may decrease the sedative activities of Epinastine.
PhenytoinThe metabolism of Epinastine can be increased when combined with Phenytoin.
PimozideThe serum concentration of Epinastine can be increased when it is combined with Pimozide.
PlasminEpinastine may increase the anticoagulant activities of Plasmin.
Platelet Activating FactorThe serum concentration of Epinastine can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Epinastine can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Epinastine.
PosaconazoleThe serum concentration of Epinastine can be increased when it is combined with Posaconazole.
PrasugrelEpinastine may increase the anticoagulant activities of Prasugrel.
PrasugrelPrasugrel may increase the antiplatelet activities of Epinastine.
PravastatinThe serum concentration of Epinastine can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Epinastine can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Epinastine can be increased when it is combined with Prednisone.
PrimidoneThe metabolism of Epinastine can be increased when combined with Primidone.
ProbenecidThe serum concentration of Epinastine can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Epinastine can be decreased when it is combined with Progesterone.
PromazineThe metabolism of Epinastine can be decreased when combined with Promazine.
PromethazineThe serum concentration of Epinastine can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Epinastine can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Epinastine can be increased when it is combined with Propranolol.
Protein CEpinastine may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeEpinastine may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe serum concentration of Epinastine can be increased when it is combined with Protriptyline.
QuazepamThe serum concentration of Epinastine can be increased when it is combined with Quazepam.
QuercetinThe serum concentration of Epinastine can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Epinastine can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Epinastine can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Epinastine can be increased when it is combined with Quinine.
RanitidineThe serum concentration of Epinastine can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Epinastine can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Epinastine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Epinastine can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Epinastine can be decreased when it is combined with Reserpine.
ResveratrolEpinastine may increase the antiplatelet activities of Resveratrol.
ReteplaseEpinastine may increase the anticoagulant activities of Reteplase.
ReviparinEpinastine may increase the anticoagulant activities of Reviparin.
RidogrelEpinastine may increase the antiplatelet activities of Ridogrel.
RifabutinThe metabolism of Epinastine can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Epinastine can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Epinastine can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Epinastine.
RilpivirineThe serum concentration of Epinastine can be increased when it is combined with Rilpivirine.
RisedronateThe serum concentration of Risedronate can be increased when it is combined with Epinastine.
RitonavirThe serum concentration of Epinastine can be decreased when it is combined with Ritonavir.
RivaroxabanEpinastine may increase the anticoagulant activities of Rivaroxaban.
RolapitantThe serum concentration of Epinastine can be increased when it is combined with Rolapitant.
RopiniroleThe metabolism of Epinastine can be decreased when combined with Ropinirole.
RosiglitazoneEpinastine may increase the anticoagulant activities of Rosiglitazone.
Salicylic acidThe risk or severity of adverse effects can be increased when Epinastine is combined with Salicylic acid.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Epinastine.
SaquinavirThe serum concentration of Epinastine can be decreased when it is combined with Saquinavir.
SCH-530348Epinastine may increase the antiplatelet activities of SCH-530348.
ScopolamineThe serum concentration of Epinastine can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Epinastine can be increased when it is combined with Selegiline.
SelexipagEpinastine may increase the anticoagulant activities of Selexipag.
SertralineThe serum concentration of Epinastine can be increased when it is combined with Sertraline.
SevofluraneEpinastine may increase the antiplatelet activities of Sevoflurane.
SildenafilThe metabolism of Epinastine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Epinastine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Epinastine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Epinastine can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Epinastine can be decreased when it is combined with Sirolimus.
SorafenibThe serum concentration of Epinastine can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Epinastine can be increased when it is combined with Spironolactone.
SRT501Epinastine may increase the antiplatelet activities of SRT501.
St. John's WortThe serum concentration of Epinastine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Epinastine can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Epinastine can be increased when it is combined with Stiripentol.
StreptokinaseEpinastine may increase the anticoagulant activities of Streptokinase.
StreptozocinThe serum concentration of Epinastine can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Epinastine can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Epinastine can be decreased when combined with Sulfisoxazole.
SulodexideEpinastine may increase the anticoagulant activities of Sulodexide.
SumatriptanThe serum concentration of Epinastine can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Epinastine can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Epinastine can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Epinastine can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Epinastine can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Epinastine can be increased when it is combined with Taurocholic Acid.
TelaprevirThe metabolism of Epinastine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Epinastine can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Epinastine can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Epinastine can be increased when it is combined with Temsirolimus.
TenecteplaseEpinastine may increase the anticoagulant activities of Tenecteplase.
TerazosinThe serum concentration of Epinastine can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Epinastine can be decreased when combined with Terbinafine.
TerfenadineThe serum concentration of Epinastine can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Epinastine can be decreased when it is combined with Tesmilifene.
TesmilifeneEpinastine may increase the antiplatelet activities of Tesmilifene.
TestosteroneThe serum concentration of Epinastine can be increased when it is combined with Testosterone.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Epinastine.
ThioridazineThe metabolism of Epinastine can be decreased when combined with Thioridazine.
ThiotepaThe metabolism of Epinastine can be decreased when combined with Thiotepa.
TicagrelorEpinastine may increase the anticoagulant activities of Ticagrelor.
TicagrelorThe serum concentration of Epinastine can be increased when it is combined with Ticagrelor.
TiclopidineEpinastine may increase the anticoagulant activities of Ticlopidine.
TiclopidineThe metabolism of Epinastine can be decreased when combined with Ticlopidine.
TinzaparinEpinastine may increase the anticoagulant activities of Tinzaparin.
TipranavirTipranavir may increase the antiplatelet activities of Epinastine.
TirofibanEpinastine may increase the anticoagulant activities of Tirofiban.
TirofibanTirofiban may increase the antiplatelet activities of Epinastine.
TocilizumabThe serum concentration of Epinastine can be decreased when it is combined with Tocilizumab.
TolvaptanThe serum concentration of Epinastine can be increased when it is combined with Tolvaptan.
TositumomabThe risk or severity of adverse effects can be increased when Epinastine is combined with Tositumomab.
TranilastEpinastine may increase the antiplatelet activities of Tranilast.
TranylcypromineThe metabolism of Epinastine can be decreased when combined with Tranylcypromine.
TrapidilEpinastine may increase the antiplatelet activities of Trapidil.
TrazodoneThe serum concentration of Epinastine can be decreased when it is combined with Trazodone.
TreprostinilEpinastine may increase the anticoagulant activities of Treprostinil.
TreprostinilTreprostinil may increase the antiplatelet activities of Epinastine.
TrifluoperazineThe serum concentration of Epinastine can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Epinastine can be increased when it is combined with Triflupromazine.
TriflusalEpinastine may increase the anticoagulant activities of Triflusal.
TriflusalTriflusal may increase the antiplatelet activities of Epinastine.
TrimethoprimThe serum concentration of Epinastine can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Epinastine can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Epinastine can be increased when it is combined with Troleandomycin.
UrokinaseEpinastine may increase the anticoagulant activities of Urokinase.
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Epinastine.
VenlafaxineThe metabolism of Epinastine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Epinastine can be decreased when combined with Verapamil.
VinblastineThe serum concentration of Epinastine can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Epinastine can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Epinastine can be increased when it is combined with Vinorelbine.
Vitamin EVitamin E may increase the antiplatelet activities of Epinastine.
VorapaxarEpinastine may increase the anticoagulant activities of Vorapaxar.
VorapaxarVorapaxar may increase the antiplatelet activities of Epinastine.
VoriconazoleThe metabolism of Epinastine can be decreased when combined with Voriconazole.
WarfarinEpinastine may increase the anticoagulant activities of Warfarin.
XimelagatranEpinastine may increase the anticoagulant activities of Ximelagatran.
ZimelidineThe serum concentration of Epinastine can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Epinastine can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Tsujii T, Yamamoto E, Ohira T, Saito N, Watanabe S: Effects of sedative and non-sedative H1 antagonists on cognitive tasks: behavioral and near-infrared spectroscopy (NIRS) examinations. Psychopharmacology (Berl). 2007 Sep;194(1):83-91. Epub 2007 May 30. [PubMed:17534605 ]
  2. Walther G, Daniel H, Bechtel WD, Brandt K: New tetracyclic guanidine derivatives with H1-antihistaminic properties. Chemistry of epinastine. Arzneimittelforschung. 1990 Apr;40(4):440-6. [PubMed:1972625 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) si...
Gene Name:
HRH2
Uniprot ID:
P25021
Molecular Weight:
40097.65 Da
References
  1. Bielory L, Ghafoor S: Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol. 2005 Oct;5(5):437-40. [PubMed:16131920 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Dupont LJ, Meade CJ, Demedts MG, Verleden GM: Epinastine (WAL 801CL) modulates the noncholinergic contraction in guinea-pig airways in vitro by a prejunctional 5-HT1-like receptor. Eur Respir J. 1996 Jul;9(7):1433-8. [PubMed:8836655 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Dupont LJ, Meade CJ, Demedts MG, Verleden GM: Epinastine (WAL 801CL) modulates the noncholinergic contraction in guinea-pig airways in vitro by a prejunctional 5-HT1-like receptor. Eur Respir J. 1996 Jul;9(7):1433-8. [PubMed:8836655 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Dupont LJ, Pype JL, Meade CJ, DeLeyn P, Deneffe G, Demedts MG, Verleden GM: Epinastine (WAL 801CL) inhibits the electrical field stimulation-induced cholinergic contraction in guinea pig and human airways in vitro. Eur Respir J. 1999 Nov;14(5):1068-75. [PubMed:10596692 ]
  2. Dupont LJ, Meade CJ, Demedts MG, Verleden GM: Epinastine (WAL 801CL) modulates the noncholinergic contraction in guinea-pig airways in vitro by a prejunctional 5-HT1-like receptor. Eur Respir J. 1996 Jul;9(7):1433-8. [PubMed:8836655 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Dupont LJ, Pype JL, Meade CJ, DeLeyn P, Deneffe G, Demedts MG, Verleden GM: Epinastine (WAL 801CL) inhibits the electrical field stimulation-induced cholinergic contraction in guinea pig and human airways in vitro. Eur Respir J. 1999 Nov;14(5):1068-75. [PubMed:10596692 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ishiguro N, Nozawa T, Tsujihata A, Saito A, Kishimoto W, Yokoyama K, Yotsumoto T, Sakai K, Igarashi T, Tamai I: Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier. Drug Metab Dispos. 2004 May;32(5):519-24. [PubMed:15100174 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23